

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IL-9 in direct ELISA.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 795908
<b>Purification</b>	Protein A or G purified from cell culture supernatant
<b>Immunogen</b>	Human embryonic kidney cell line HEK293-derived human IL-9 Met1-Ile144 Accession # P15248
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

<b>Neutralization</b>	Measured by its ability to neutralize IL-9-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. <i>et al.</i> (1988) Br. J. Haematol. <b>69</b> :359. The Neutralization Dose (ND <sub>50</sub> ) is typically 1-5 µg/mL in the presence of 2 ng/mL Recombinant Human IL-9.
-----------------------	--

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Human IL-9 was originally identified as a cytokine found in the conditioned medium of a human T cell leukemia virus type I (HTLV-I) transformed T cell line that is mitogenic for the factor-dependent human megakaryoblastic leukemic cell line, M07e. The cDNA encoding this cytokine was subsequently isolated by functional expression cloning and found to be similar to the mouse T cell growth factor III/P40. This human cytokine and its murine homologue are now designated as human and mouse IL-9. Besides HTLV-I or -II transformed T cell lines, rhIL-9 is also produced by activated human PBLs. Human IL-9 was also reported to be expressed by primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells derived from Hodgkin's disease patients, suggesting a possible role for rhIL-9 in the development of the pathophysiology of Hodgkin's disease.

Human and murine IL-9 are also capable of enhancing *in vitro* survival of human T cell lines as well as synergizing with Epo to support erythroid colony formation *in vitro*. However, the mast cell enhancing activity associated with rhIL-9 has not yet been demonstrated in the human system and no human IL-9-dependent T cell clones have been identified.

The gene for rhIL-9 has been mapped to human chromosome 5. As in the mouse system, the human IL-9 cDNA encodes a 144 amino acid residue precursor protein with an 18 amino acid signal peptide that is cleaved to form the mature cysteine-rich protein with a predicted molecular mass of 14 kDa. Human IL-9 contains four potential N-linked glycosylation sites and the native rhIL-9 is a highly glycosylated protein. Human and mouse IL-9 share 56% and 67% homology at the amino acid and nucleotide levels, respectively. Although murine IL-9 is active on human cells, human IL-9 is not active on mouse cells.